Grants & giving

Strengthening Community-Driven Care

Submit an Application for a Medical Educational Grant

May 5, 2015

May 5, 2015

At Johnson & Johnson, we’re building a more inclusive and connected health system by supporting independent training and education initiatives. We are proud to provide grants that support eligible organizations in offering independent continuing medical education for healthcare professionals – including physicians, nurses, residents, and pharmacists – by enhancing their skills and knowledge in meeting the needs of patients and the community.

Requests for educational grants are evaluated consistent with appropriate internal and external guidelines and policies. We prioritize support in areas of therapeutic interest, and are particularly interested in initiatives that support communities facing barriers to equitable healthcare access and representation.

Apply now:

Click here to visit our Grant Portal where you can submit a medical education grant.

NEW Hematology RFP:

2025 BsAb Combinations RFP Due Date January 14, 2026

Funding decisions:

Following an internal review process, you will be notified of the status of your application within 90 days of a completed submission and no additional information is required.

Delivery Methods:

Delivery methods vary per therapeutic area. They may include live and virtual activities, dinner programs, grand rounds, and on-site engagements with healthcare teams, ensuring our grants reach diverse audiences within the healthcare community.

Areas of Interest:

Neuroscience

Schizophrenia - Adults with Schizophrenia

Earlier adoption of long-acting injectable antipsychotics (LAI)
Clinical stability & persistency through advancing patients to a longer dosing interval
Switching oral antipsychotics to long-acting injectable antipsychotics
Schizophrenia and burden of illness (e.g. brain health, mortality)
Effects and dynamics of a therapeutic alliance between the treatment team (incl nurse practitioners & pharmacists) and patient/caregiver to co-create a treatment plan early in the patient journey helping patients progress through their treatment plan
Patient & caregiver preferences in LAI utilization
Patterns of antipsychotic LAI utilization in communities and populations experiencing systemic inequities (including social determinants of health)
Competency models assessing injection techniques in the administration of atypical antipsychotic LAIs
Antipsychotic LAI transition of care models (inpatient to outpatient)
Champion the destigmatization of schizophrenia to encourage compassion and acceptance
Education on third-generation antipsychotics covering topics such as safety, relapse and appropriate dosing in schizophrenia

Mood - Treatment Resistant Depression - Major Depressive Disorder in adults with inadequate response to 2 or more antidepressants

Treatment resistant depression (TRD) in clinical practice: clinical presentation of patients with inadequate response to two oral antidepressants in the same depressive episode
TRD: early adult patient identification & treatment initiation
APP role in the diagnosis and treatment of TRD
Collaborative and patient-centric approach for treatment decision making in TRD
Remission as a target in TRD treatment
Mechanistic rationale to pharmacological treatment approaches
Treatment approaches in TRD including interventional treatments
Strategies for preventing relapse in TRD, and the impact of relapse prevention
Impact MDD & TRD in communities and populations experiencing systemic inequities

Mood – Major Depressive Disorder

Burden of MDD with Insomnia Symptoms
- Increased suicidality
- Higher relapse/worse
- Impairments in cognition, functioning, QoL
Bidirectional relationship between sleep and depression
- Insomnia and MDD may be part of a single disease pathophysiology – rather than 2 separate comorbidities
Role of orexin system in MDD
Patient Perspective MDDIS
- Burden of next day sedation
- Reluctance in discussing insomnia with HCPs
- Impact on functioning/QoL

Oncology

Multiple Myeloma

Smoldering Multiple Myeloma & Newly Diagnosed

Risk Stratification and diagnostic criteria
New & emerging data
Transplant eligible/ineligible NDMM
Maintenance therapy
Understanding the role of MRD in defining or adapting duration of therapy
High Risk patients, including elderly and minority patients
Applying guideline based care for Triplet & Quad based therapy

Relapsed Refractory

MOA and clinical use of BCMA & GPRC5D targeting bispecific antibodies (BsAbs)
New & emerging data for novel combinations of CD-38 & BsAbs
Emerging data for bsab and early relapse (1-3 prior lines of therapy)
Optimal therapy for patient groups (high risk, elderly, etc)
Integration of BsAbs into practice
- RWE
- In patient/out-patient strategies for step up dosing
- Patient selection
Bridging therapy for BCMA CAR-T
- Comparison CD-19 CAR-T bridging strategies & BCMA strategies
New & emerging data in CAR-T therapy; data on use in earlier line of therapy, long term data and application to practice (including RWE & CT data)
Collaboration & Coordination between community & transplant centers
Sequencing of bispecifics and CAR-T
Patient Selection/Eligibility
- Optimal therapy for patient groups (high risk, elderly, etc)
AE mitigation and management
- BCMA CAR-T related Neurotoxicities (e.g., CRS, ICANS, Parkinsonian symptoms, SPD) mitigation and management and differentiation from CD-19 CAR-T AEs
Care Coordination (Academic/Community HCPs)
Outpatient Administration & Remote Monitoring

Acute Myeloid Leukemia

MOA, scientific rationale and clinical use of menin inhibitors for treatment ofAML
New & emerging data related to menin inhibitors including frontline combinations and the role of maintenance
New & emerging treatment options using menin inhibitors for treatment of RR AML
Menin inhibitor related AEs
NPM1 & KMT2A Driver mutations- recognizing the significance and impact on treatment options
- Role of mutational testing, interpretation of results, and implications for treatment decisions

Oncology- Solid Tumor

Bladder Cancer (BC)

Mechanism of action (MOA)
Management and prevention of adverse events
Shared decision-making to increase patient/HCP communication, patient adherence and outcomes
Novel bladder-sparing therapies and MOAs
Clinical Trial data
Collaboration and communication strategies among multidisciplinary teams to enhance patient outcomes (referrals)

Prostate Cancer (PC)

Current and new therapies for treatment for PC
Treatment intensification
Molecular pathways involved in different stages of prostate cancer
Management and prevention of adverse events
Clinical trial data (ORR, PFS, OS)
Dosing and Administration
Understand the strategies to address unmet needs for treating prostate cancer

Non-small Cell Lung (NSCLC)

Current and new therapies for treatment for NSCLC
Management and prevention of adverse events (Incorporating prophylactic supportive care)
Clinical trial data (ORR, PFS, OS)
Dosing and Administration
Shared decision-making to increase patient/HCP communication, patient adherence and outcomes

Head and Neck Squamous Cell Carcinoma

Current and new therapies for treatment for HNSCC
Mechanisms of treatment resistance in HNC
Management and prevention of adverse events
Clinical trial data (ORR, mPFS, mOS)
Dosing and Administration
Epidemiology and risk factors associated with HNC
Collaboration and communication strategies among multidisciplinary teams to enhance patient outcomes (referrals)

Colorectal Cancer

Current and new therapies for treatment for CRC
Management and prevention of adverse events
Clinical trial data (ORR, mPFS, mOS)
Dosing and Administration
Collaboration and communication strategies among multidisciplinary teams to enhance patient outcomes (referrals)

Autoantibody

Generalized myasthenia gravis(gMG)

Pediatric/adolescent treatment
Guideline updates
Disease and treatment response monitoring strategies in practice
Importance of antibody testing
Steroid Reduction and sustained (MSE) Minimal Symptom Expression as treatment goals

Immunology

Gastroenterology

Crohn’s Disease (CD) and Ulcerative Colitis (UC)

IBD Disease State Awareness
Early diagnosis and identification of suboptimally-treated patients with moderately to severely active UC and CD
Efficacy and safety of advanced therapies in the treatment of patients with moderately to severely active UC and CD
- Efficacy in achieving short term outcomes (eg early symptomatic response) and long-term endoscopic outcomes including deep remission (composite of clinical remission & endoscopic remission), and the clinical relevance of achieving endoscopic remission and deep remission
- Special populations/clinically relevant patient subgroups within moderately to severely active UC and CD (eg fistulizing disease, ileal Crohn’s, EIMs)
Mechanism of action and routes of administration of advanced therapies including p19IL-23 therapies

Dermatology

Psoriasis (PsO)

Treatment gaps in the management of PsO
Diagnosis, differential diagnosis, and management of PsO
Evolution of the treatment paradigm for PsO
Assess the severity of PsO
Recent guideline updates for treatment of PsO and impact in the real-world
Address gaps in care in underserved/undertreated patients with PsO
Support ongoing professional development with fellowships and educational programs
Clinical trial or real-world data for emerging oral therapies in PsO management including head-to-head comparisons and long-term data
Current and emerging therapies for PsO, with a focus on IL-23 inhibitors, orals, their MOA, and the latest safety, efficacy, or real-world evidence
Clinical and immunologic factors involved in the progression of PsO to PsA
Shared inflammatory pathways linking the gut, skin, and joints to support integrated patient care.

Rheumatology

Psoriatic Arthritis (PsA)

Treatment gaps in the management of PsA
Diagnosis and management of PsA, including various manifestations/subtypes of PsA
Early diagnosis, identification, and management of Axial PsA
PsA Disease State Awareness
Clinical trial efficacy and safety data in PsA management
Current guideline developments
Support ongoing professional development with fellowships and educational programs
Early diagnosis and identification of suboptimally-treated patients with PsA, and axial PsA
Efficacy and safety of advanced therapies in the treatment of patients with PsA
Structural damage and the importance of early detection and effective treatment
Clinical and immunologic factors involved in the progression of PsO to PsA
Shared inflammatory pathways linking the gut, skin, and joints to support integrated patient care.

Ankylosing Spondylitis (AS)

AS Disease state awareness
Clinical, imaging, and genetic differences between AS and Axial PsA
Clinical trial efficacy and safety data in AS management
Current guideline developments
Support ongoing professional development with fellowships and educational programs
Early diagnosis and identification of suboptimally-treated patients with AS
Efficacy and safety of advanced therapies in the treatment of patients with AS

Rheumatoid Arthritis (RA)

RA Disease state awareness
Clinical trial efficacy and safety data in RA management
Current guideline developments
Support ongoing professional development with fellowships and educational programs
Early diagnosis and identification of suboptimally-treated patients with RA
Efficacy and safety of advanced therapies in the treatment of patients with RA

Sjögren’s Disease (SjD)

SjD Disease state awareness
Sjögren’s MOD and FcRN biology
FcRN as a targeted mechanism of action for SjD versus deep B-cell depletion
Clinical trial efficacy and safety data in SjD management
Current guideline developments
Support ongoing professional development with fellowships and educational programs
Early diagnosis and identification of suboptimally-treated patients with SjD
Efficacy and safety of advanced therapies in the treatment of patients with SjD